Zenocutuzumab clinical trials show whether efficacy is stable

Zenocutuzumab is an innovative bispecific antibody drug that specifically targets HER2 and HER3 and is designed to interrupt the tumor signaling pathway driven by the formation of HER2/HER3 heterodimers. Its original design was to solve the problem of insufficient efficacy of traditional HER2 or HER3 single-target treatments in certain tumors. Especially in solid tumors harboring NRG1 fusion mutations, zeltolizumab is demonstrating significant therapeutic potential.

In clinical trials, zetolizumab has been used to treat a variety of advanced solid tumors carrying NRG1 fusions, including pancreatic cancer, non-small cell lung cancer, cholangiocarcinoma, etc. Based on published preliminary data from the EARLIER and eNRGy studies, zetolizumab demonstrated good objective response rates ( ORR), in some tumor types, ORR reaches more than , and some patients even achieve sustained remission for more than one year. This shows that its efficacy is relatively stable in patients with specific molecular types and has the possibility of long-term treatment.

From the perspective of efficacy maintenance, zetolizumab not only demonstrated initial response capability in patients with NRG1 fusion positive, but also had positive signals in terms of median progression-free survival (PFS) and duration of response (DoR). For example, in the non-small cell lung cancer population, some patients continued to benefit from zetolizumab for more than 12 months. Although the sample size is still small, the trend shows that under strict molecular screening, the stability of the efficacy is guaranteed.

In summary, zetolizumab has shown relatively stable efficacy in current clinical trials, and is especially suitable for patients with solid tumors carrying NRG1 fusion mutations. Its unique mechanism of targeting HER2/HER3 dimers provides new therapeutic possibilities for patients who have failed traditional treatments. However, since it is still in the research stage, large-scaleIIIThe results of phase 1 clinical trials will be an important basis for judging the durability and stability of its efficacy. For patients with NRG1 fusion-positive tumors, zetolizumab is undoubtedly a new precision treatment option worth looking forward to.

Reference materials:https://www.drugs.com/